Prevalence, mechanisms, and management of cancer-related cognitive impairment

International Review of Psychiatry

Volumn 26, Issue 1, 2014, Pages 102-113

  Janelsins, Michelle C ^a   Kesler, Shelli R ^b   Ahles, Tim A ^c   Morrow, Gary R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTENTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELATED COGNITIVE IMPAIRMENT; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; EXECUTIVE FUNCTION; HEREDITY; HUMAN; MEMORY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; ANIMAL; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; PSYCHOLOGY;

ANIMALS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS;

EID: 84896885977     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.864260     Document Type: Article

References (129)

1. Abraham, J., Haut, M.W., Moran, M.T., Filburn, S., Lemiuex, S. & Kuwabara, H. (2008). Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clinical Breast Cancer, 8, 88-91
2. ACS. (2013). Cancer Facts and Figures 2013. Atlanta: American Cancer Society
3. Ahles, T.A., Root, J.C. & Ryan, E.L. (2012). Cancer-And cancer treatment-Associated cognitive change: An update on the state of the science. Journal of Clinical Oncology, 30, 3675-3686
4. Ahles, T.A. & Saykin, A.J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7, 192-201
5. Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., Silberfarb, P.M. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493
6. Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F., Hanscom, B.S., Kaufman, P.A. (2008). Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treament, 110, 143-152. doi: 10.1007/s10549-007-9686-5
7. Ahles, T.A., Saykin, A.J., McDonald, B.C., Li, Y., Furstenberg, C.T., Hanscom, B.S., Kaufman, P.A. (2010). Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. Journal of Clinical Oncology, 28, 4434-4440. doi: 10.1200/JCO.2009.27.0827
8. Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B. & Mott, L.A. (2003). The relationship of APOE genotype to neuropsychological performance in long-Term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12, 612-619. doi: 10.1002/pon.742
9. Barton, D.L., Burger, K., Novotny, P.J., Fitch, T.R., Kohli, S., Soori, G., Loprinzi, C.L. (2013). The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Supportive Care in Cancer, 21, 1185-1192. doi: 10.1007/s00520-012-1647-9
10. Bender, C.M., Sereika, S.M., Berga, S.L., Vogel, V.G., Brufsky, A.M., Paraska, K.K. & Ryan, C.M. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15, 422-430. doi: 10.1002/pon.964
11. Biglia, N., Bounous, V.E., Malabaila, A., Palmisano, D., Torta, D.M., D Alonzo, M., Torta, R. (2012). Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: A prospective study. European Journal of Cancer Care, 21, 485-492. doi: 10.1111/j.1365-2354. 2011.01320.x
12. Bradley, C.J., Neumark, D., Bednarek, H.L. & Schenk, M. (2005). Short-Term effects of breast cancer on labor market attachment: Results from a longitudinal study. Journal of Health Economics, 24, 137-160. doi: S0167-6296(04)00098-0 p.10.1016/j.jhealeco.2004.07.003
13. Brezden, C.B., Phillips, K.A., Abdolell, M., Bunston, T. & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701
14. Brown, M.S., Stemmer, S.M., Simon, J.H., Stears, J.C., Jones, R.B., Cagnoni, P.J. & Sheeder, J.L. (1998). White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. American Journal of Neuroradiology, 19, 217-221
15. Bruno, J., Hosseini, S.M. & Kesler, S. (2012). Altered resting state functional brain network topology in chemotherapytreated breast cancer survivors. Neurobiology of Disease, 48, 329-338. doi: 10.1016/j.nbd.2012.07.009
16. Castellon, S.A., Ganz, P.A., Bower, J.E., Petersen, L., Abraham, L. & Greendale, G.A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955-969
17. Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Meyers, C.A., Lee, B.N. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer, 97, 2919-2925. doi: 10.1002/cncr.11382
18. Collins, B., Mackenzie, J., Stewart, A., Bielajew, C. & Verma, S. (2009). Cognitive effects of chemotherapy in postmenopausal breast cancer patients 1 year after treatment. Psycho-oncology, 18, 134-143. doi: 10.1002/pon.1379
19. Conroy, S.K., McDonald, B.C., Ahles, T.A., West, J.D. & Saykin, A.J. (2013). Chemotherapy-induced amenorrhea: A prospective study of brain activation changes and neurocognitive correlates. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9240-5
20. Correa, D.D. & Hess, L.M. (2012). Cognitive function and quality of life in ovarian cancer. Gynecologic Oncology, 124, 404-409. doi: 10.1016/j.ygyno.2011.11.005
21. Correa, D.D., Zhou, Q., Thaler, H.T., Maziarz, M., Hurley, K. & Hensley, M.L. (2010). Cognitive functions in longterm survivors of ovarian cancer. Gynecologic Oncology, 119, 366-369. doi: 10.1016/j.ygyno.2010.06.023
22. Dantzer, R. & Kelley, K.W. (2007). Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 21, 153-160. doi: 10.1016/j.bbi.2006.09.006
23. Debess, J., Riis, J.O., Engebjerg, M.C. & Ewertz, M. (2010). Cognitive function after adjuvant treatment for early breast cancer: A population-based longitudinal study. Breast Cancer Research and Treatment, 121, 91-100. doi: 10.1007/s10549-010-0756-8
24. Deprez, S., Amant, F., Smeets, A., Peeters, R., Leemans, A., Van Hecke, W., Sunaert, S. (2012). Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. Journal of Clinical Oncology, 30, 274-281. doi: 10.1200/JCO.2011.36.8571
25. Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Van den Stock, J., Sunaert, S. (2011). Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human Brain Mapping, 32, 480-493. doi: 10.1002/hbm.21033
26. de Ruiter, M.B., Reneman, L., Boogerd, W., Veltman, D.J., Caan, M., Douaud, G., Schagen, S.B. (2012). Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Human Brain Mapping, 33, 2971-2983. doi: 10.1002/hbm.21422
27. de Ruiter, M.B., Reneman, L., Boogerd, W., Veltman, D.J., van Dam, F.S., Nederveen, A.J., Schagen, S.B. (2011). Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping, 32, 1206-1219. doi: 10.1002/hbm.21102
28. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M. & Noble, M. (2006). CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. Journal of Biology, 5, 22. doi: Jbiol50 [pii]10.1186/jbiol50
29. Dumas, J.A., Makarewicz, J., Schaubhut, G.J., Devins, R., Albert, K., Dittus, K. & Newhouse, P.A. (2013). Chemotherapy altered brain functional connectivity in women with breast cancer: A pilot study. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9244-1
30. Fan, H.G., Houede-Tchen, N., Yi, Q.L., Chemerynsky, I., Downie, F.P., Sabate, K. & Tannock, I.F. (2005). Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1-And 2-year follow-up of a prospective controlled study. Journal of Clinical Oncology, 23, 8025-8032. doi: 10.1200/JCO.2005.01.6550
31. Fardell, J.E., Vardy, J. & Johnston, I.N. (2013). The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sciences. doi: 10.1016/j.lfs.2013.05.006
32. Fardell, J.E., Vardy, J., Johnston, I.N. & Winocur, G. (2011). Chemotherapy and cognitive impairment: Treatment options. Clinical Pharmacology and Therapeutics, 90, 366-376. doi: 10.1038/clpt.2011.112
33. Fardell, J.E., Vardy, J., Logge, W. & Johnston, I. (2010). Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacology, Biochemistry, and Behavior, 97, 333-339. doi: 10.1016/j. pbb.2010.08.019
34. Fardell, J.E., Vardy, J., Shah, J.D. & Johnston, I.N. (2012). Cognitive impairments caused by oxaliplatin and 5-fl uorouracil chemotherapy are ameliorated by physical activity. Psycho pharmacology, 220, 183-193. doi: 10.1007/s00213-011-2466-2
35. Ferguson, R.J., McDonald, B.C., Rocque, M.A., Furstenberg, C.T., Horrigan, S., Ahles, T.A. & Saykin, A.J. (2012). Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psycho-Oncology, 21, 176-186. doi: 10.1002/pon.1878
36. Ferguson, R.J., McDonald, B.C., Saykin, A.J. & Ahles, T.A. (2007). Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology, 25, 3866-3870. doi: 10.1200/JCO.2007.10.8639
37. Ganz, P.A., Bower, J.E., Kwan, L., Castellon, S.A., Silverman, D.H., Geist, C., Cole, S.W (2013). Does tumor necrosis factor-Alpha (TNF-Alpha) play a role in post-chemotherapy cerebral dysfunction? Brain, Behavior, and Immunity, 30, S99-108. doi: 10.1016/j.bbi.2012.07.015
38. Han, R., Yang, Y.M., Dietrich, J., Luebke, A., Mayer-Proschel, M. & Noble, M. (2008). Systemic 5-fl uorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology, 7, 12. doi: Jbiol69 [pii]10.1186/jbiol69
39. Hedayati, E., Alinaghizadeh, H., Schedin, A., Nyman, H. & Albertsson, M. (2012). Effects of adjuvant treatment on cognitive function in women with early breast cancer. European Journal of Oncology Nursing, 16, 315-322. doi: 10.1016/j.ejon.2011.07.006
40. Helal, G.K., Aleisa, A.M., Helal, O.K., Al-Rejaie, S.S., Al-Yahya, A.A., Al-Majed, A.A. & Al-Shabanah, O.A. (2009). Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-Treated rats. Oxidative Medicine and Cellular Longevity, 2, 26-35
41. Hermelink, K., Henschel, V., Untch, M., Bauerfeind, I., Lux, M.P. & Munzel, K. (2008). Short-Term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study. Cancer, 113, 2431-2439. doi: 10.1002/cncr.23853
42. Hermelink, K., Untch, M., Lux, M.P., Kreienberg, R., Beck, T., Bauerfeind, I. & Munzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer, 109, 1905-1913. doi: 10.1002/cncr.22610
43. Hosseini, S.M. & Kesler, S.R. (2013). Multivariate pattern analysis of fMRI in breast cancer survivors and healthy women. Journal of the International Neuropsychological Society 18 : 1-11. [Epub ahead of print].
44. Hosseini, S.M., Koovakkattu, D. & Kesler, S.R. (2012). Altered small-world properties of gray matter networks in breast cancer. BMC Neurology, 12, 28. doi: 10.1186/1471-2377-12-28
45. Hsieh, T.C., Wu, Y.C., Yen, K.Y., Chen, S.W. & Kao, C.H. (2013). Early changes in brain FDG metabolism during anticancer therapy in patients with pharyngeal cancer. Journal of Neuroimaging. doi: 10.1111/jon.12006
46. Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K.S., Lachs, M.S., Holland, J. (2006). Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics Society, 54, 925-931. doi: 10.1111 /j.1532-5415.2006.00732.x
47. Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., Uchitomi, Y. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109, 146-156. doi: 10.1002/cncr.22368
48. Janelsins, M.C., Kohli, S., Mohile, S.G., Usuki, K., Ahles, T.A. & Morrow, G.R. (2011). An update on cancer-And chemotherapyrelated cognitive dysfunction: Current status. Seminars in Oncology, 38, 431-438. doi: 10.1053/j.seminoncol.2011. 03.014
49. Janelsins, M.C., Mustian, K.M., Palesh, O.G., Mohile, S.G., Peppone, L.J., Sprod, L.K., Morrow, G.R. (2012). Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research. Supportive Care in Cancer, 20, 831-839. doi: 10.1007/s00520-011-1158-0
50. Janelsins, M.C., Roscoe, J.A., Berg, M.J., Thompson, B.D., Gallagher, M.J., Morrow, G.R., Gross, R.A. (2010). IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Investigation, 28, 544-553. doi: 10.3109/0735790 0903405942
51. Jansen, C.E., Cooper, B.A., Dodd, M.J. & Miaskowski, C.A. (2011). A prospective longitudinal study of chemotherapyinduced cognitive changes in breast cancer patients. Supportive Care in Cancer, 19, 1647-1656. doi: 10.1007/s00520-010-0997-4
52. Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828-834. doi: 6603029 [pii]10.1038/sj.bjc.6603029
53. Joshi, G., Hardas, S., Sultana, R., St Clair, D.K., Vore, M. & Butterfield, D.A. (2007). Glutathione elevation by gammaglutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. Journal of Neuroscience Research, 85, 497-503. doi: 10.1002/jnr.21158
54. Kesler, S. (in press). Default mode network as a potential biomarker of chemotherapy-related brain injury and altered brain aging. Neurobiology of Aging
55. Kesler, S., Hadi Hosseini, S.M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K. & Morrow, G. (2013a). Cognitive training for improving executive function in chemotherapytreated breast cancer survivors. Clinical Breast Cancer, 13, 299-306. doi: 10.1016/j.clbc.2013.02.004
56. Kesler, S., Janelsins, M., Koovakkattu, D., Palesh, O., Mustian, K., Morrow, G. & Dhabhar, F.S. (2013b). Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-Alpha levels in chemotherapy-Treated breast cancer survivors. Brain, Behavior, and Immunity, 30, S109-116. doi: 10.1016/j. bbi.2012.05.017
57. Kesler, S.R., Bennett, F.C., Mahaffey, M.L. & Spiegel, D. (2009). Regional brain activation during verbal declarative memory in metastatic breast cancer. Clinical Cancer Research, 15, 6665-6673. doi: 10.1158/1078-0432.CCR-09- 1227
58. Kesler, S.R., Kent, J.S. & O Hara, R. (2011). Prefrontal cortex and executive function impairments in primary breast cancer. Archives of Neurology, 68, 1447-1453. doi: 10.1001/archneurol. 2011.245
59. Kesler, S.R., Watson, C., Koovakkattu, D., Lee, C., O Hara, R., Mahaffey, M.L. & Wefel, J.S. (2013a). Elevated prefrontal myoinositol and choline following breast cancer chemotherapy. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9228-1
60. Kesler, S.R., Wefel, J.S., Hosseini, S.M., Cheung, M., Watson, C.L. & Hoeft, F. (2013b). Default mode network connectivity distinguishes chemotherapy-Treated breast cancer survivors from controls. Proceedings of the National Academy of the Sciences of the United States of America, 110, 11600-11605. doi: 10.1073/pnas.1214551110
61. Kohli, S., Fisher, S.G., Tra, Y., Adams, M.J., Mapstone, M.E., Wesnes, K.A., Morrow, G.R. (2009). The effect of modafi nil on cognitive function in breast cancer survivors. Cancer, 115, 2605-2616. doi: 10.1002/cncr.24287
62. Kohli, S., Griggs, J.J., Roscoe, J.A., Jean-Pierre, P., Bole, C., Mustian, K.M., Morrow, G.R. (2007). Self-reported cognitive impairment in patients with cancer. Journal of Oncology Practice, 3, 54-59. doi: 10.1200/JOP.0722001
63. Konat, G.W., Kraszpulski, M., James, I., Zhang, H.T. & Abraham, J. (2008). Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metabolic Brain Disease, 23, 325-333. doi: 10.1007/s11011-008-9100-y
64. Koppelmans, V., Breteler, M.M., Boogerd, W., Seynaeve, C., Gundy, C. & Schagen, S.B. (2012). Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology, 30, 1080-1086. doi: 10.1200/JCO.2011.37.0189
65. Korkaya, H., Liu, S. & Wicha, M.S. (2011). Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation, 121, 3804-3809. doi: 10.1172/JCI57099
66. Lai, J.S., Butt, Z., Wagner, L., Sweet, J.J., Beaumont, J.L., Vardy, J., Cella, D. (2009). Evaluating the dimensionality of perceived cognitive function. Journal of Pain and Symptom Management, 37, 982-995. doi: 10.1016/j. jpainsymman. 2008.07.012
67. Loef, M. & Walach, H. (2012). Fruit, vegetables and prevention of cognitive decline or dementia: A systematic review of cohort studies. Journal of Nutrition, Health and Aging, 16, 626-630
68. Loef, M. & Walach, H. (2013). Midlife obesity and dementia: Meta-Analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity, 21, E51-55. doi: 10.1002/oby.20037
69. Lower, E.E., Fleishman, S., Cooper, A., Zeldis, J., Faleck, H., Yu, Z. & Manning, D. (2009). Effi cacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. Journal of Pain and Symptom Management, 38, 650-662. doi: 10.1016/j.jpainsymman. 2009.03.011
70. Lundorff, L.E., Jonsson, B.H. & Sjogren, P. (2009). Modafi nil for attentional and psychomotor dysfunction in advanced cancer: A double-blind, randomised, cross-over trial. Palliative Medicine, 23, 731-738. doi: 10.1177/0269216309106872
71. Lyons, L., ELBeltagy, M., Bennett, G. & Wigmore, P. (2012). Fluoxetine counteracts the cognitive and cellular effects of 5-fl uorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLOS ONE, 7, e30010. doi: 10.1371/journal.pone.0030010
72. Lyons, L., ELBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G. & Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology, 215, 105-115. doi: 10.1007/s00213-010-2122-2
73. Mar Fan, H.G., Clemons, M., Xu, W., Chemerynsky, I., Breunis, H., Braganza, S. & Tannock, I.F. (2008). A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Supportive Care in Cancer, 16, 577-583. doi: 10.1007/s00520-007-0341-9
74. McAllister, T.W., Ahles, T.A., Saykin, A.J., Ferguson, R.J., McDonald, B.C., Lewis, L.D., Rhodes, C.H. (2004). Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Current Psychiatry Reports, 6, 364-371
75. McDonald, B.C., Conroy, S.K., Ahles, T.A., West, J.D. & Saykin, A.J. (2010). Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Research and Treatment, 123, 819-828. doi: 10.1007/s10549-010-1088-4
76. McDonald, B.C., Conroy, S.K., Ahles, T.A., West, J.D. & Saykin, A.J. (2012). Alterations in brain activation during working memory processing associated with breast cancer and treatment: A prospective functional magnetic resonance imaging study. Journal of Clinical Oncology, 30, 2500-2508. doi: 10.1200/JCO.2011.38.5674
77. McDonald, B.C., Conroy, S.K., Smith, D.J., West, J.D. & Saykin, A.J. (2013). Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study. Brain, Behavior, and Immunity, 30, S117-125. doi: 10.1016/j.bbi.2012.05.007
78. Mehlsen, M., Pedersen, A.D., Jensen, A.B. & Zachariae, R. (2009). No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy . Psycho-Oncology, 18, 248-257. doi: 10.1002/pon.1398
79. Meyers, C.A., Albitar, M. & Estey, E. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 104, 788-793. doi: 10.1002/cncr.21234
80. Mills, P.J., Ancoli-Israel, S., Parker, B., Natarajan, L., Hong, S., Jain, S., von Kanel, R. (2008). Predictors of infl ammation in response to anthracycline-based chemotherapy for breast cancer. Brain, Behavior, and Immunity, 22, 98-104. doi: S0889-1591(07)00162-6 [pii]10.1016/j.bbi.2007.07.001
81. Morley, K.I. & Montgomery, G.W. (2001). The genetics of cognitive processes: Candidate genes in humans and animals. Behavior Genetics, 31, 511-531
82. Morrow, G.R., Shelke, A.R., Roscoe, J.A., Hickok, J.T. & Mustian, K. (2005). Management of cancer-related fatigue. Cancer Investigation, 23, 229-239
83. Mustian, K.M., Sprod, L.K., Janelsins, M., Peppone, L.J. & Mohile, S. (2012). Exercise recommendations for cancerrelated fatigue, cognitive impairment, sleep problems, depression, pain, anxiety, and physical dysfunction: A review. Oncology and Hematology Review, 8, 81-88
84. Myers, J.S. (2012). Chemotherapy-related cognitive impairment: The breast cancer experience. Oncology Nursing Forum, 39 (1), E31-40. doi: 10.1188/12.ONF.E31-E40
85. Nelson, C.J., Lee, J.S., Gamboa, M.C. & Roth, A.J. (2008). Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer, 113, 1097-1106. doi: 10.1002/cncr.23658
86. Oh, B., Butow, P.N., Mullan, B.A., Clarke, S.J., Beale, P.J., Pavlakis, N., Vardy, J. (2012). Effect of medical Qigong on cognitive function, quality of life, and a biomarker of infl ammation in cancer patients: A randomized controlled trial. Supportive Care in Cancer, 20, 1235-1242. doi: 10.1007/s00520-011-1209-6
87. Ouimet, L.A., Stewart, A., Collins, B., Schindler, D. & Bielajew, C. (2009). Measuring neuropsychological change following breast cancer treatment: An analysis of statistical models. Journal of Clinical and Experimental Neuropsychology, 31, 73-89. doi: 793717043 [pii]10.1080/13803390801992725
88. Palesh, O., Peppone, L., Innominato, P.F., Janelsins, M., Jeong, M., Sprod, L., Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151-162. doi: 10.2147/NSS.S18895
89. Palmer, J.L., Trotter, T., Joy, A.A. & Carlson, L.E. (2008). Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. Journal of Cancer Survivorship, 2, 275-282. doi: 10.1007/s11764-008-0070-1
90. Paraska, K. & Bender, C.M. (2003). Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncology Nursing Forum, 30, 473-478. doi: 10.1188/03.ONF.473-478
91. Pomykala, K.L., Ganz, P.A., Bower, J.E., Kwan, L., Castellon, S.A., Mallam, S., Silverman, D.H. (2013). The association between pro-infl ammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9243-2
92. Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., Hortobagyi, G.N. (2004). Changes in plasma levels of infl ammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 25, 94-102
93. Quesnel, C., Savard, J. & Ivers, H. (2009). Cognitive impairments associated with breast cancer treatments: Results from a longitudinal study. Breast Cancer Research and Treatment, 116, 113-123. doi: 10.1007/s10549-008- 0114-2
94. Raffa, R.B. (2011). A proposed mechanism for chemotherapyrelated cognitive impairment (' chemo-fog ') . Journal of Clinical Pharmacy and Therapeutics, 36, 257-259. doi: 10.1111/j.1365-2710.2010.01188.x
95. Rego, S.L., Helms, R.S. & Dreau, D. (2013). Tumor necrosis factor-Alpha-converting enzyme activities and tumor-Associated macrophages in breast cancer. Immunologic Research. doi : 10.1007/s12026-013-8434-7
96. Reid-Arndt, S.A. & Cox, C.R. (2012). Stress, coping and cognitive defi cits in women after surgery for breast cancer. Journal of Clinical Psychology in Medical Settings, 19, 127-137. doi: 10.1007/s10880-011-9274-z
97. Reid-Arndt, S.A., Matsuda, S. & Cox, C.R. (2012). Tai chi effects on neuropsychological, emotional, and physical functioning following cancer treatment: A pilot study. Complementary Therapies in Clinical Practice, 18, 26-30. doi: 10.1016/j.ctcp.2011.02.005
98. Reid-Arndt, S.A., Yee, A., Perry, M.C. & Hsieh, C. (2009). Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. Journal of Psychosocial Oncology, 27, 415-434. doi: 10.1080/07347330903183117
99. Reiriz, A.B., Reolon, G.K., Preissler, T., Rosado, J.O., Henriques, J.A., Roesler, R. & Schwartsmann, G. (2006). Cancer chemotherapy and cognitive function in rodent models: Memory impairment induced by cyclophosphamide in mice. Clinical Cancer Research, 12, 5000; author reply 5000-5001. doi: 10.1158/1078-0432.CCR-06-0138
100. Reuter-Lorenz, P.A. & Cimprich, B. (2013). Cognitive function and breast cancer: Promise and potential insights from functional brain imaging. Breast Cancer Research and Treatment, 137, 33-43. doi: 10.1007/s10549-012-2266-3
101. Ryan, J.L., Carroll, J.K., Ryan, E.P., Mustian, K.M., Fiscella, K. & Morrow, G.R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12, S22-34. doi: 10.1634/theoncologist.12-S1-22
102. Schagen, S.B., Boogerd, W., Muller, M.J., Huinink, W.T., Moonen, L., Meinhardt, W. & Van Dam, F.S. (2008). Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncologica, 47, 63-70. doi: 10.1080/02841860701518058
103. Schagen, S.B., Muller, M.J., Boogerd, W., Mellenbergh, G.J. & van Dam, F.S. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742-1745. doi: 10.1093/jnci/djj470
104. Schilder, C.M., Eggens, P.C., Seynaeve, C., Linn, S.C., Boogerd, W., Gundy, C.M., Schagen, S.B. (2009). Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional fi ndings from the neuropsychological TEAM-side study. Acta Oncologica, 48, 76-85. doi: 902183905 p. 10.1080/02841860802314738
105. Schilder, C.M., Seynaeve, C., Beex, L.V., Boogerd, W., Linn, S.C., Gundy, C.M., Schagen, S.B. (2010). Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology, 28 (8), 1294-1300. doi: JCO.2008.21.3553 p. 10.1200/JCO.2008.21.3553
106. Schilder, C.M., Seynaeve, C., Linn, S.C., Boogerd, W., Beex, L.V., Gundy, C.M., Schagen, S.B. (2012). Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study. Psycho-Oncology, 21, 479-487. doi: 10.1002/pon.1928
107. Seigers, R. & Fardell, J.E. (2011). Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neuroscience and Biobehavioral Reviews, 35, 729-741
108. Sherwin, B.B. (2012). Estrogen and cognitive functioning in women: Lessons we have learned. Behavioral Neuroscience, 126, 123-127. doi: 10.1037/a0025539
109. Shilling, V., Jenkins, V., Morris, R., Deutsch, G. & Bloomfield, D. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer-Preliminary results of an observational longitudinal study. Breast, 14, 142-150. doi: 10.1016/j.breast.2004.10.004
110. Small, B.J., Rawson, K.S., Walsh, E., Jim, H.S., Hughes, T.F., Iser, L., Jacobsen, P.B. (2011). Catechol-O-methyltransferase (COMT) genotype modulates cancer treatment-related cognitive defi cits in breast cancer survivors. Cancer, 117, 1369-1376
111. Sprod, L.K., Mohile, S.G., Demark-Wahnefried, W., Janelsins, M.C., Peppone, L.J., Morrow, G.R., Mustian, K.M. (2012). Exercise and cancer treatment symptoms in 408 newly diagnosed older cancer patients. Journal of Geriatric Oncology, 3, 90-97. doi: 10.1016/j.jgo.2012.01.002
112. Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S. & Bielajew, C. (2008). The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psycho-Oncology, 17, 122-130. doi: 10.1002/pon.1210
113. Swayampakula, A.K., Alkhouri, N., Haut, M.W. & Abraham, J. (2007). Cognitive impairment with signifi cant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer. Clinical Advances in Hematology and Oncology, 5, 985-987; discussion 987-988
114. Tager, F.A., McKinley, P.S., Schnabel, F.R., El-Tamer, M., Cheung, Y.K.K., Fang, Y.X., Hershman, D.L. (2011). The cognitive effects of chemotherapy in post-menopausal breast cancer patients: A controlled longitudinal study [Erratum]. (2010, 123, 25-34). Breast Cancer Research and Treatment, 126, 271-272. doi: 10.1007/s10549-009-0684-7
115. Tangpong, J., Cole, M.P., Sultana, R., Estus, S., Vore, M., St Clair, W., Butterfield, D.A. (2007). Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. Journal of Neurochemistry, 100, 191-201. doi: JNC4179 p. 10.1111/j.1471-4159.2006.04179.x
116. Tangpong, J., Cole, M.P., Sultana, R., Joshi, G., Estus, S., Vore, M., Butterfield, D.A. (2006). Adriamycin-induced, TNF-Alpha-mediated central nervous system toxicity. Neuro biology of Disease, 23, 127-139. doi: 10.1016/j.nbd.2006. 02.013
117. van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., vd Wall, E., Droogleever Fortuyn, M.E. & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218
118. Vardy, J., Dhillon, H., Pond, G.R., Rourke, S., Xu, W., Renton, C., Tannock, I.F. (2012). Cognitive function in colorectal cancer patients: Interim analysis of a longitudinal prospective study. J Clin Oncol Supp. abs. 9021, [Abstract].
119. Vardy, J., Wong, K., Yi, Q.L., Park, A., Maruff, P., Wagner, L. & Tannock, I.F. (2006). Assessing cognitive function in cancer patients. Supportive Care in Cancer, 14, 1111-1118. doi: 10.1007/s00520-006-0037-6
120. Vardy, J.L., Booth, C., Pond, G.R., Zhang, H., Dhillon, S., Clarke, S.J. & Tannock, I.F. (2007). Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. [Abstract 9070]. Journal of Clinical Oncology, ASCO Proceedings Supplement
121. Vearncombe, K.J., Rolfe, M., Wright, M., Pachana, N.A., Andrew, B. & Beadle, G. (2009). Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal of the International Neuropsychological Society, 15, 951-962. doi: S1355617709990567 p.10.1017/S1355617709990567
122. Villani, F., Busia, A., Villani, M., Vismara, C., Viviani, S. & Bonfante, V. (2008). Serum cytokine in response to chemoradiotherapy for Hodgkin s disease. Tumori, 94, 803-808
123. Von Ah, D., Carpenter, J.S., Saykin, A., Monahan, P., Wu, J., Yu, M., Unverzagt, F. (2012). Advanced cognitive training for breast cancer survivors: A randomized controlled trial. Breast Cancer Research and Treatment, 135, 799-809. doi: 10.1007/s10549-012-2210-6
124. Wagner, L., Sweet, J., Butt, Z., Lai, J., Cella, D. (2009). Measuring patient self-reported cognitive function: Development of the Functional Assessment of Cancer Therapy-Cognitive Function instrument. Journal of Supportive Oncology, 7, 32-39
125. Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N. & Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292-2299. doi: 10.1002/cncr.20272
126. Wefel, J.S., Saleeba, A.K., Buzdar, A.U. & Meyers, C.A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 116, 3348-3356. doi: 10.1002/cncr.25098
127. Wefel, J.S., Vardy, J., Ahles, T. & Schagen, S.B. (2011). International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncology, 12, 703-708. doi: 10.1016/S1470-2045(10) 70294-1
128. Wieneke, M.H. & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66
129. Yoshikawa, E., Matsuoka, Y., Inagaki, M., Nakano, T., Akechi, T., Kobayakawa, M., Uchitomi, Y. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Research and Treatment, 92, 81-84. doi: 10.1007/s10549-005-1412-6